HRT & Heart Health: The 2024 Evidence Update (Without the Hype)

If you're hearing that hormone therapy is either a miracle or a menace, you're not alone. The truth is more nuanced, and that nuance matters for cardiovascular outcomes.

In 2024, the conversation shifted meaningfully: not because we suddenly "discovered" estrogen, but because we've gotten better at answering two questions the early 2000s era often blurred together:

1. Who is starting hormone therapy? (Age, time since menopause, baseline risk)
2. What are they starting? (Route and formulation)

This article breaks down what changed, what didn't, and how I frame the decision in clinic.

The short version

• Menopausal hormone therapy (MHT/HRT) is not indicated to prevent cardiovascular disease.
• For healthy, symptomatic women who start near menopause, the overall benefit–risk profile is often favorable, especially for vasomotor symptoms and quality of life.
• Timing matters ("critical window"): starting earlier tends to carry lower cardiovascular risk than starting much later.
• Formulation matters: oral vs transdermal vs vaginal routes have different effects on clotting and lipid/inflammation pathways.
• The right decision is almost always individualized, based on symptoms, goals, and baseline cardiovascular and thrombotic risk.

Why 2002 changed everything, and why 2024 is recalibrating it

The Women's Health Initiative (WHI) trials (early 2000s) were landmark randomized studies. They also created a lasting public-health shockwave.

A key detail: many participants were older (average age ~63) and years beyond menopause at initiation. That matters because vascular biology and plaque stability aren't the same at 52 as at 63.

After WHI, utilization dropped sharply, and "black box warning" era messaging often became too broad, treating all hormone therapy as one homogeneous exposure.

Fast-forward: we now have decades of additional follow-up and newer observational data with age-appropriate cohorts and real-world formulations, plus updated professional guidance emphasizing individualized risk assessment.

Timing is everything: the "critical window" idea

Think of menopausal hormone therapy like many therapies in prevention: the same intervention can behave differently depending on when you start it.

A practical framework I use:

0–10 years since menopause: often the "optimal window"

• Lowest overall cardiovascular risk signal in most data sets
• Best symptom relief per risk trade-off for many patients

10–15 years: "caution zone"

• Needs tighter cardiovascular risk stratification
• Decision becomes more case-by-case

>15 years: generally higher risk

• Higher likelihood of subclinical atherosclerosis and plaque burden
• Less favorable benefit–risk profile for initiating systemic therapy

Important caveat: timing isn't the only variable; baseline risk factors, prior events, and thrombotic history may outweigh the calendar.

Formulation matters: not all HRT is created equal

A simple way to remember this is first-pass liver effect.

Oral estrogen: more hepatic signaling

Oral estrogen goes through the liver first, which can:

• increase certain clotting factors
• raise triglycerides in some people
• influence inflammatory pathways

That's one reason oral regimens are more consistently linked to higher venous thromboembolism (VTE) risk than transdermal estrogen in many observational analyses.

Transdermal estrogen (patch/gel): a different risk profile

Transdermal estrogen enters systemic circulation directly, minimizing first-pass hepatic effects and is generally associated with:

• lower VTE risk compared with oral estrogen (especially at standard doses)
• a more neutral impact on triglycerides

Vaginal estrogen: minimal systemic exposure (for GSM)

For genitourinary syndrome of menopause (GSM), vaginal dryness, dyspareunia, urinary symptoms, low-dose vaginal estrogen is designed to be primarily local with minimal systemic levels, which often shifts the benefit–risk profile more favorably for many patients who don't need systemic symptom relief.

What about heart attacks and stroke?

Here's the most honest framing:

• In randomized trials focused on older initiators (like WHI's average age), hormone therapy does not reduce cardiovascular events and may increase some risks depending on regimen and patient factors.
• In younger, closer-to-menopause initiators, some data suggest more neutral or potentially favorable cardiovascular patterns, especially for coronary outcomes, though the evidence varies by formulation and study design.

So the clinical takeaway is not "HRT prevents heart attacks."
It's: If HRT is appropriate for symptoms, starting earlier and selecting lower-risk formulations may reduce avoidable harm.

The risk conversation: what I screen for every time

Before I even talk dosing, I do a quick "risk gate":

1) Cardiovascular risk

• ASCVD history (MI, stroke/TIA, PAD)
• Hypertension, diabetes, CKD, smoking, family history
• Lipids (including ApoB and Lp(a) when appropriate)
• If uncertainty: consider CAC scoring in select patients to refine risk

2) Thrombotic risk (VTE)

• Prior DVT/PE
• Thrombophilia history
• Strong provoking factors (recent surgery, immobility)
• Migraine with aura (nuanced), obesity, smoking, age, etc.

3) Breast and endometrial considerations

• Personal breast cancer history or very high risk
• Uterus present? (If yes, estrogen generally requires endometrial protection)

4) Symptoms and goals

• Hot flashes/night sweats, sleep, mood, quality of life
• GSM symptoms
• Bone health priorities

A practical "how we decide" flow (clinic-style)

1. Confirm indication

   • Systemic HRT: moderate-to-severe vasomotor symptoms, sometimes prevention of bone loss in select cases
   • Vaginal estrogen: GSM symptoms

2. Timing check

   • 0–10 years since menopause tends to be the most favorable risk window

3. Choose the route thoughtfully

   • Higher VTE risk? → prefer transdermal (often)
   • GSM only? → vaginal estrogen
   • Lipid issues/triglycerides? → consider transdermal

4. Dose and duration

   • Use the lowest effective dose
   • Reassess periodically (at least annually)

5. Risk mitigation

   • Optimize BP, lipids, glucose, weight, sleep, and physical activity
   • If smoking: quitting is non-negotiable for long-term cardiovascular risk

What changed in 2024?

Many clinicians and professional groups increasingly emphasize that blanket, one-size-fits-all warnings can:

• discourage appropriate care for symptomatic women
• obscure the meaningful differences between oral vs transdermal vs vaginal therapy
• ignore the "timing" variable, which is often the pivot point in cardiovascular risk

There's a broader clinical push toward:

• formulation-specific counseling
• age-appropriate cohorts in evidence interpretation
• shared decision-making grounded in current data, not 20-year-old generalizations

What I tell patients in one sentence

Hormone therapy isn't a heart-prevention treatment, but for the right patient, started at the right time, in the right form, it can be a safe and highly effective way to treat menopausal symptoms.

References (IG-friendly, no links)

• Women's Health Initiative (WHI) trials, early 2000s (estrogen + progestin; estrogen-alone arms)
• Manson JE, et al. Menopausal hormone therapy and long-term mortality. JAMA. 2017;318(10):927–938.
• AHA Scientific Statement: Rethinking Menopausal Hormone Therapy. Circulation. 2023;147:597–610.
• Johansson T, et al. Contemporary menopausal hormone therapy and cardiovascular disease risk. BMJ. 2024;387:e078784.
• Pinkerton JAV. Hormone therapy for postmenopausal women. N Engl J Med. 2020.

Educational content only. Not medical advice. Decisions about HRT should be individualized with a clinician who can assess personal cardiovascular, thrombotic, and cancer-related risks.